Recombinant HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (ab215338)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EPR1899(2)] to JAK1 (phospho Y1034 + Y1035)
- Suitable for: Dot blot, WB
- Reacts with: Human
- Conjugation: HRP
Related conjugates and formulations
Overview
-
Product name
HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)]
See all JAK1 primary antibodies -
Description
HRP Rabbit monoclonal [EPR1899(2)] to JAK1 (phospho Y1034 + Y1035) -
Host species
Rabbit -
Conjugation
HRP -
Tested applications
Suitable for: Dot blot, WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark. -
Storage buffer
pH: 7.40
Preservative: 0.1% Proclin 300 Solution
Constituents: 1% BSA, 30% Glycerol (glycerin, glycerine), PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR1899(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab215338 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Dot blot |
1/1000.
|
|
WB |
1/1000. Detects a band of approximately 133 kDa (predicted molecular weight: 133 kDa).
|
Notes |
---|
Dot blot
1/1000. |
WB
1/1000. Detects a band of approximately 133 kDa (predicted molecular weight: 133 kDa). |
Target
-
Function
Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. Kinase partner for the interleukin (IL)-2 receptor. -
Tissue specificity
Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain. -
Domain
Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
The FERM domain mediates interaction with JAKMIP1. -
Cellular localization
Endomembrane system. Wholly intracellular, possibly membrane associated. - Information by UniProt
-
Database links
- Entrez Gene: 3716 Human
- Omim: 147795 Human
- SwissProt: P23458 Human
- Unigene: 207538 Human
-
Alternative names
- JAK 1 antibody
- JAK 1A antibody
- JAK 1B antibody
see all
Images
-
All lanes : HRP Anti-JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (ab215338) at 1/1000 dilution
Lane 1 : Untreated Ramos cells
Lanes 2-3 : Ramos cells treated with pervanadateat at 1mM for 30min
Predicted band size: 133 kDa
Observed band size: 133 kDa
Exposure time: 5 seconds -
Dot blot analysis of JAK1 (phospho Y1034 + Y1035) antibody [EPR1899(2)] (HRP) (ab215338) at 1/1000 dilution.
Lane 1: JAK1 (phospho Y1034) phospho peptide.
Lane 2: JAK1 (phospho Y1035) phospho peptide.
Lane 3: JAK1 (phospho Y1034 + Y1035) phospho peptide.
Lane 4: JAK1 non phospho peptide.Blocking and diluting buffer and concentration: 5% NFDM/TBST. Exposure time: 3 minutes.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (7)
ab215338 has been referenced in 7 publications.
- Liang Y et al. Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis. Exp Ther Med 22:875 (2021). PubMed: 34194553
- Cui J et al. Skullcapflavone I has a potent anti-pancreatic cancer activity by targeting miR-23a. Biofactors 46:821-830 (2020). PubMed: 32141657
- Shi Q et al. microRNA-29a functions as a tumor suppressor in nasopharyngeal carcinoma 5-8F cells through targeting VEGF. Iran J Basic Med Sci 22:541-546 (2019). PubMed: 31217935
- Gong W et al. Deletion of long noncoding RNA EFNA3 aggravates hypoxia-induced injury in PC-12 cells by upregulation of miR-101a. J Cell Biochem 120:836-847 (2019). PubMed: 30125989
- Cui J et al. WITHDRAWN: Skullcapflavone I has a potent anti-pancreatic cancer activity by targeting miR-23a. Life Sci N/A:N/A (2019). PubMed: 31085241
- Li Y et al. Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway. BMC Cancer 18:1230 (2018). PubMed: 30526546
- Yin D et al. Pro-Angiogenic Role of LncRNA HULC in Microvascular Endothelial Cells via Sequestrating miR-124. Cell Physiol Biochem 50:2188-2202 (2018). PubMed: 30415256